Aptamer researchers – A growing community

Aptamers are a new class of molecules with a great potential to rival monoclonal antibodies in therapeutic, diagnostic, analytical as well as basic research applications. Described just over two decades ago, there has been an ever growing interest in these molecules as evidenced by the considerable increase in the number of related publications. Furthermore, the field of aptamer technology received a great boost in 2004 after the first FDA approved drug, Macugen, to treat age related macular degeneration, and later the development of the first aptamer based diagnostic platform for the analysis of mycotoxins in grain. In subsequent years there has been an outstanding growth in the Aptamer based companies and the range of developed products. This shows that aptamers are here to stay!

Join the International Society on Aptamers today – It is a free platform for the growing community of aptamer researchers from academia and industry.